Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease

americanpharmaceuticalreviewApril 07, 2021

Tag: Syndax , axatilimab , cGVHD , AGAVE-201

PharmaSources Customer Service